SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) announced today it will form a Biosurgery Business Unit focused on maximizing the commercial potential of RECOTHROM® Thrombin, topical (Recombinant). Stephen W. Zaruby has been hired to lead the new division and will also serve as President of ZymoGenetics, effective January 2, 2009.
